Basic Information
Kyttaro, a subsidiary of Cambridge Science (CSC), is a UK-based clinical-stage bioscience company developing innovative therapies to treat hypertriglyceridemia, atherosclerotic cardiovascular disease, inflammation, and neurogastrointestinal disorders. Focused on advancing first-in-class biologics for the treatment of inflammatory, metabolic, gastrointestinal, and cardiovascular diseases, Kyttaro aims to improve global health and enhance patients' lives.